The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
HLA-DRB1*07:01-DQA1*02:01 and UGT1A1*28 allele carriage in hepatic serious adverse event cases identified during lapatinib clinical trials.
C. F. Spraggs
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
L. R. Budde
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
L. P. Briley
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
C. Cox
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
E. Rappold
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
G. Aktan
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
L. S. Williams
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
V. E. Mooser
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
L. R. Cardon
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline